RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,249 | +126.8% | 7,092 | +121.4% | 0.00% | – |
| Q2 2023 | $23,924 | +16.7% | 3,203 | +4.2% | 0.00% | – |
| Q1 2023 | $20,502 | -31.7% | 3,074 | -22.8% | 0.00% | – |
| Q4 2022 | $30,000 | -16.7% | 3,984 | +17.7% | 0.00% | – |
| Q3 2022 | $36,000 | +63.6% | 3,385 | +23.5% | 0.00% | – |
| Q2 2022 | $22,000 | -18.5% | 2,740 | -28.0% | 0.00% | – |
| Q1 2022 | $27,000 | -50.0% | 3,808 | +19.9% | 0.00% | – |
| Q4 2021 | $54,000 | 0.0% | 3,175 | +32.6% | 0.00% | – |
| Q3 2021 | $54,000 | -21.7% | 2,395 | +26.7% | 0.00% | – |
| Q2 2021 | $69,000 | – | 1,890 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |